THE MONOTHERAPY ANTIDEPRESSANT PIPELINE PROBLEM: ONLY 8 APPROVALS OUT OF 28 ATTEMPTS IN THE LAST 25 YEARS

Introduction

Although more than twenty-five antidepressant are currently available for clinical use, most were developed serendipitously over the past seven decades and are based on a limited set of mechanisms, including monoamine oxidase inhibition, serotonergic reuptake modulation, and more recently, N-methyl-D-aspartate (NMDA) receptor activity. We postulated that advances in chemistry and improvements in clinical trial methodology would lead to development of newer mechanisms. However, such progress has not materialized over the past twenty-five years. Using reporting requirements mandated under the U.S. Food and Drug Administration Modernization Act, we examined registered monotherapy clinical trials on ClinicalTrials.gov conducted between 2000 and 2025.

Methods

We searched ClinicalTrials.gov using the following criteria: “Major Depressive Disorder,” “Completed Studies,” “Phase 2, 3,” “Interventional Studies,” “Studies with Results,” and “Funded by Industry” from January 1, 2000 to December 12, 2025. Clinical trial data for gepirone were obtained from the FDA AccessData database after it was not identified in the initial search. We excluded pediatric trials, non placebo controlled studies, adjunctive therapies, contraindicated conditions, antidepressants approved before 2000, and trials without MADRS or HAM-D as the primary endpoint. From eligible trials, we extracted data on drug name, trial duration, primary endpoint, year of approval or current development status, baseline and change in MADRS or HAM-D scores, and number of trial participants. To quantify the effectiveness of investigational antidepressants, standardized changes in depression rating scale scores were summarized using standardized mean differences expressed as Cohen’s d.

Results

Our review identified twenty-eight new antidepressant development programs initiated by large pharmaceutical companies during this period. Our initial search identified 235 clinical trials. After eligibility screening, 50 trials met inclusion criteria and were included in the analysis. We identified 28 antidepressant development programs, of which eight resulted in FDA-approved antidepressants; their years of approval and mean effect sizes are: escitalopram (2002, 0.15), vortioxetine (2013, 0.26), desvenlafaxine succinate sustained release (2008, 0.15), vilazodone (2011), levomilnacipran extended release (2013, 0.27), intranasal esketamine (2019, 0.49), and gepirone (2023, 0.24), dextromethorphan-bupropion (2022, 0.34). Approved medications were significantly more likely to have trials enrolling ≥100 participants per treatment arm compared with non-approved medications (χ² = 15.2, df = 1, p < 0.0001).

Discussion

All approved antidepressants act through well-established mechanisms of action and were supported by adequately powered clinical trials demonstrating significant improvements in depressive symptoms. In contrast, the remaining development programs generally enrolled smaller sample sizes and pursued novel therapeutic targets that failed to demonstrate sufficient efficacy during clinical testing. Six exploratory programs achieved an effect size ≥0.3 but did not reach the market due to insufficient efficacy or corporate decisions (n = 3), while the remaining programs remain under investigation (n = 3). In this context, relapse-prevention trial designs and alternative therapeutic modalities, including medium-to large-molecule approaches adapted from treatments for diabetes and obesity, may represent the most promising avenues for future development, potentially benefiting from similar elements of serendipity.